Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
FTC
CJ Bioscience
★
CJ Bioscience Annual Disclosure: Maintains Financial Stability with 18.6% Debt Ratio, but Continues Losses from R&D Investment
06/01/2026, 03:58 PM
PERI
CJ Bioscience
★★
CJ Bioscience: Key Pipeline CJRB-101 Clinical Trial Terminated Early, Q1 Losses Continue
05/15/2026, 05:01 PM
EXCH
CJ Bioscience
★★★
Early Termination and Voluntary Withdrawal of Microbiome Immuno-Oncology Drug CJRB-101 Phase 1/2 Trial
05/12/2026, 05:34 PM